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With a prevalence of 34% (55/162 at-risk recipients) and a mortality of 25% 
(14/55 affected recipients), obliterative bronchiolitis is the most significant 
long-term complication after pulmonary transplantation. Because of its im- 
portance, we examined onor-recipient characteristics and antecedent clinical 
events to identify factors associated with development ofobliterative bronchi- 
olitis, which might be eliminated or modified to decrease its prevalence. We 
also compared treatment outcome between recipients whose diagnosis was 
made early by surveillance transbronchial lung biopsy before symptoms or 
decline in pulmonary function were present versus recipients whose diagnosis 
was made later when symptoms or declines in pulmonary function were 
present. Postoperative airway ischemia, an episode of moderate or severe acute 
rejection (grade IH/IV), three or more episodes of histologic grade II (or 
greater) acute rejection, and cytomegalovirus disease were risk factors for 
development of obliterative bronchiolitis. Recipients with obliterative bronchi- 
olitis detected in the preclinical stage were significantly more likely to be in 
remission than recipients who had clinical disease at the time of diagnosis: 
81% (13/15) versus 33% (13/40); p < 0.05. These results indicate that acute 
rejection is the most significant risk factor for development of obliterative 
bronchiolitis and that obliterative bronchiolitis responds to treatment with 
augmented immunosuppression when it is detected early by surveillance 
transbronchial biopsy. (J TrIORAC CARDIOVASC SURG 1995;110:4-14) 
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era of lung transplantation began in 1981.1 Primarily 
because survival is improving, lung and heart-lung 
transplantation have become acceptable therapeutic 
modalities2, 3 However, better survival has come 
principally from improvements in early postopera- 
tive care, including improved donor and recipient 
selection, 4 lung preservation, 5 management of isch- 
emia/reperfusion lung injury, 6 and recognition and 
treatment of infections caused by bacteria, 7 Pneu- 
mocystis, 8 and cytomegalovirus (CMV). 9'10 As a 
result, survival to hospital discharge after lung trans- 
plantation has improved from approximately 50% to 
60% 10 years ago to 70% to 90% today. 
The primary determinant of long-term survival is 
obliterative bronchiolitis (OB)J  1 With a prevalence 
of 30% to 40% in long-term survivors, OB has 
emerged as the most significant long-term compli- 
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Table I. Characteristics of lung recipients at risk for the development of OB 
Early Late Overall 
(1982-1987) (1988-1992) (1982-1992) 
Gender 
Male 12 (39%) 58 (44%) 70 
Female 19 (61%) 73 (56%) 92 
Age (yr) 
Mean z standard eviation 32 z 10 36 _+ 15 35 T 14 
Range 4-48 1-64 1-64 
Transplant procedure 
Single lung 0 45 (34%)* 45 
Bilateral ung 0 57 (44%)* 57 
Heart and lung 31 (100%) 29 (22%)* 60 
Pretransplant disease 
Primary pulmonary hypertension 14 (45%) 31 (24%)* 45 
Secondary pulmonary hypertension 13 (42%) 22 (17%)* 35 
Emphysema 0 33 (25%)* 33 
Septic lung disease 3 (10%) 23 (18%) 26 
Restrictive lung disease 1 (3%1 9 (7%) 10 
Other 0 13 (10%) 13 
Immunosuppression 
Cyclosporine 31 (100%) 86 (66%)* 117 
FK 506 0 38 (29%) 38 
Switch: cyclosporine---~FK 506 0 6 (5%) 6 
Switch: FK 506=-~cyclosporine 0 1 (1%) 1 
Total number 31 131 162 
"p < 0.01, by X 2 test. 
cation after pulmonary transplantation. Although 
the exact pathogenesis of posttransplantation OB 
remains unclear, the bulk of  the evidence suggests 
that OB occurs as a result of an immunologic 
reaction against or by an ischemic injury to the 
epithelial cells of the airways. 11-17 
Because the pathogenesis of OB after lung trans- 
plantation is unclear, one purpose of  this study was 
to elucidate factors that might be important in the 
pathogenesis of  OB. We examined recipient and 
donor characteristics, as well as clinical events be- 
fore development of OB, to determine whether these 
characteristics or events were related to the sfibse- 
quent development of OB. The second pu~ose  of this 
study was to determine .whether early diagnosis and 
treatment with augmented immunosuppression af- 
fected long-term outcome of recipients with this dis- 
order. We compared survival and functional outcome, 
of recipients whose OB was discovered before symp- 
toms or pulmonary function abnormalities were 
present with the outcome of recipients whose OB was 
discovered when symptoms or pulmonary function 
abnormalities were present. 
Methods 
Patient population. Because histologic and clinical OB 
has not been observed in the first 60 days after transplan- 
tation, this study included only the 162 pulmonary trans- 
plant recipients who survived more than 60 days and were 
discharged from the hospital after the transplant proce- 
dure (Table I). Because significant changes in the man- 
agement of pulmonary transplant recipients occurred at 
the end of 1987, we analyzed and compared separately our 
early (1982 to 1987) and late (1988 to 1992) experience. 
These management changes included use of surveillance 
transbronchial lung biopsy (TBBx), is prophylactic antibi- 
otics tailored to the results of microbiologic ultures 
obtained from the airways of the donor and recipient at 
the time of transplantation, 7 CMV-negative blood and 
blood products for seronegative donors and recipients, 
and ganciclovir for treatment and prophylaxis of CMV 
illness in seropositive recipients or donors or both. 9' ao 
Because of the evolution of lung transplant procedures, 
indications, and immune suppression over time, there 
were significantly fewer heart-lung procedures, recipients 
with pulmonary hypertension, and recipients treated with 
cyclosporine-based immunosuppression in the later as 
compared with the early period. 
Definitions 
OB. OB was defined according to histologic (n - 52) 19 
or clinical criteria (n = 3). 20 Histologically active OB was 
defined by the presence of dense eosinophilic scar tissue 
in the airway walls with a mononuclear cell infiltrate. 
Inactive OB was defined by the presence of scar tissue in 
the airway wall but without a mononuclear cell infiltrate. 19 
Criteria for the clinical diagnosis of OB included symp- 
toms of dyspnea nd/or cough with or without sputum 
and/or a new obstructive and/or restrictive pulmonary 
function defect that could not be explained by the pres- 
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Table II. Severity of  the OB based on change in 
FEV1 from baseline value 
Stage Severity FEV1 (L) 
0 None >--85% of baseline 
1 Mild 70%-84% of baseline 
2 Moderate 55%-69% of baselnie 
3 Severe <55% of baseline 
4 Dead Death due to OB 
FEV1, Forced expiratory volume in 1 second. 
ence of bronchomalacia, stenosis of the anastomosis, or
infection in the allograft. The clinical diagnosis and sever- 
ity of OB were defined by a decline in the expiratory 
volume in the first second of a forced vital capacity 
maneuver compared with a baseline value defined as the 
average of the two previous highest consecutive measure- 
ments taken 3 to 6 weeks apart at least 3 months after lung 
transplantation (Table 11). 20 
Recipients with OB were divided into four groups on 
the basis of clinical status and method of diagnosis (Tables 
II and III). OB in group 1 recipients was identified only by 
surveillance TBBx when no symptoms or pulmonary func- 
tion changes were present. OB in group 2 recipients was 
identified by TBBx after a new pulmonary function abnor- 
mality was present. OB in group 3 recipients was identi- 
fied by TBBx when symptoms and pulmonary function 
changes were present. OB in group 4 recipients was 
identified by methods other than TBBx. 
Acute rejection. Acute rejection was defined by histo- 
logic criteria. 19 Only histologically confirmed episodes 
that occurred before the development of OB were in- 
cluded in this analysis. 
Bacterial pneumonia. Bacterial pneumonia was defined 
by histologic or clinical criteria. Clinical criteria included 
fever, new or increased radiographic nfiltrates, and bac- 
teria recovered from the allograft in a sputum or bron- 
choalveolar lavage specimen sufficient o warrant a full 
course of antibiotic .therapy. Episodes occurring in the 
first 2 months after transplantation were analyzed sepa- 
rately from those occurring later. 
CMV illness. CMV infection was defined by the pres- 
ence of CMV in a culture obtained from ar~y body site in 
the absence of Symptoms of CMV infection, histologic 
evidence of CMV disease, rejection, or the isolation of any 
other infectious pathogen. CMV disease was defined by a 
positive culture for CMV plus the presence of intracellu- 
lar inclusions typical of CMV in cells or tissue obtained 
from any body site. CMV syndrome was defined by the 
presence of CMV in a culture from any body site plus 
symptoms typical for CMV infection that were not related 
to rejection or isolation of any other infectious pathogens. 
Our five episodes of CMV syndrome have been included 
in the CMV infection group for the purpose of this 
analysis. 
Airway ischemia. Airway ischemia was defined by the 
presence of intensely erythematous, friable, edematous 
airways in the allograft as seen bronchoscopically without 
evidence of airway infection. Such changes usually re- 
solved within 14 to 21 days after transplantation. 
Table I I I .  Methods used to detect OB 
Period 
Early Late Total 
t1982-1987) (1988-1992) (1982-1992) 
Group 1 0 
Group 2 3 
Group 3 6 
Group 4 9 
Clinical 3 
OLBx 4 
Autopsy 2 
Total 18 
15 15 
10 13 
11 17 
1 10 
37 55 
Group 1. Surveillance TBBx with no symptoms and stable pulmonary 
function; group 2, TBBx and decreased pulmonary function; group 3, TBBx 
and symptoms with or without decreased pulmonary function; group 4. 
diagnosis made by methods other than TBBx: OLBx. open lung biopsy. 
Adult respiratory distress syndrome. Adult respiratory 
distress yndrome was defined clinically by the presence of 
radiographic infiltrates in the absence of volume overload, 
infection, or rejection or histologically by the presence of 
diffuse alveolar damage. 
Panel reactive antibody (PRA). Pretransplantation se-
rum samples were tested for complement-dependent lym- 
phocytotoxic antibody activity against a 45 to 60 cell panel 
of donors typed by human leukocyte antigen (HLA) who 
were selected to represent most known HLA antigens. 21
These serum samples were tested with or without dithio- 
treitol, which inactivates immunoglobulin M antibodies 
and allows for detection of more significant immunoglob- 
ulin G antibodies. 22A significant response was defined by 
the detection of lymphocytotoxic antibody activity in 10% 
or more of the cell panels. 
Immunosuppression. Postoperative immunosuppres- 
sion included azathioprine, corticosteroids, and cyclospo- 
rine or FK 506, as previously described 23 (Table I). 
Immediately before transplantation, azathioprine 4 mg/kg 
and methylprednisolone 5 mg/kg were administered intra- 
venously. Either cyclosporine or FK 506 was begun after 
the operation by continuous infusion as soon as the 
recipient was in hemodynamically stable condition. Recip- 
ients were switched to oral preparations of these medica- 
tions after extubation. The dose of cyclosporine was 
titrated to maintain a blood level of 800 to 1000 ng/ml by 
the Abbott Laboratories TD'x method. The dose of FK 506 
was titrated to maintain a blood level of 1.0 to 1.5 ng/ml by 
an enzyme-linked immunosorbent assay method. The dose 
of azathioprine was titrated to maintain a white blood cell 
count of about 5000/mm 3. Prednisone 10 to 15 mg/day was 
begun after the second episode of acute rejection. 
The first episode and sometimes the second episode 
of acute rejection were treated with methylprednisolone 
1 gm intravenously each day for 3 days. Intramuscular 
rabbit antithymocyte globulin 1.5 mg/kg per day for 5 days 
was administered sometimes for the second and always for 
any subsequent episodes of acute rejection. 
OB was treated with the antilymphocyte agents, rabbit 
antithymocyte globulin 1.5 mg/kg per day for 5 days or 
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Table IV. Effect of the method of diagnosis on 
outcome of OB 
Group l Group2 Group3 Group4 
OuWome No. % No. % No. % No. % 
Resolved 12 80 1 7 2 12 2 20 
Stable 1 7 4 31 2 12 2 20 
Decl ine 2 13 4 31 6 35 3 30 
Dead 0 0 4 31 7 41 3 30 
Total  ' 15 100 13 100 17 100 10 100 
Resolved, Without histologic active OB, stable forced expiratory volume in 
1 second, and no symptoms; Stable, current stage is the same as it was at 
the time of diagnosis; Decline, current stage is higher than at the time of 
diagnosis. 
Minnesota antilymphocyte globulin 10 to 15 mg/kg per 
day for 14 days, or with methylprednisolone 1 gm intra- 
venously each day for 3 days. Response to treatment was 
assessed by histologic examination, symptoms, and forced 
expiratory volume in 1 second (Table If). The process was 
considered "resolved" if no symptoms or pulmonary func- 
tion changes were present (persistent stage 0) and fol- 
low-up TBBx revealed inactive or no OB (Table IV). The 
process was considered stable if symptoms, pulmonary 
function, or histologic findings remained unchanged after 
treatment. Continued decline was defined as increased 
symptoms and further deterioration i  pulmonary func- 
tion resulting from histologically active OB despite treat- 
ment. 
Assessment of treatment. The function of the allograft 
was assessed by history, physical examination, chest radi- 
ography, arterial blood gases, spirometry, and fiberoptic 
bronchoscopy with bronchoalveolar lavage and TBBx 
every 3 months during the first year after transplantation. 
every 4 months during the second year. twice a year 
thereafter, and whenever infection or rejection was sus- 
pected. The response to treatment for OB and acute 
rejection was assessed with the aforementioned studies 4 
to 6 weeks after the administration ofmethylprednisolone 
and 6 to 8 weeks after the administration of antilympho- 
cytic agents. 
Statistical analysis. Possible risk factors (Table V) for 
development of OB were analyzed by univariate (X 2) and 
Cox multivariate analysis for our early (1982 to 1987), late 
(1988 to 1992), and overall experience (1982 to 1992) 
(Tab le  V I ) .  24 Computations were performed with SPSS 
(SPSS Inc., Chicago, I!1.) and BMDPIL programs (BMDP 
Software, Los Angeles, Calif.). Actuarial freedom from 
OB for each risk factor was computed by life table analysis 
and compared by the generalized Wilcoxon test (Figs. 1 to 
3). 25 Changes in the severity of OB from the time of 
diagnosis to the present (April 30, 1993) (Fig. 4) were 
compared for each diagnostic group as outlined in Table 
III using the Wilcoxon signed rank test, and comparisons 
among the four diagnostic groups were made by the 
Kruskal-Wallis statistic. 26 The impact of treatment on 
outcome in each diagnostic group, was compared by X 2 
analysis (Table IV). Ap  value of 0.05 or less was consid- 
ered significant. 
Table V. Possible risk factors for the development 
of OB 
A: Indices analyzed in early (1982-1987), late t1988-1992), and 
overall (1982-1992) experience 
Recipient Age 
Gender 
Date of transplantation 
Underlying disease 
Type of transplant procedure 
Requirement for CPB 
ABO blood type 
CMV serology 
Immunosuppression (cyclosporine 
or FK 506) 
Donor Age 
Gender 
Ischemic time 
ABO blood type 
CMV serology 
Donor-recipient match Gender 
ABO blood type 
CMV 
Complications after ARDS, DAD 
transplantation Airway ischemia 
Bacterial pneumonia (early and 
late) 
CMV infection 
CMV disease 
Pneumocystis 
PTLD 
Acute rejection (frequency) 
Acute rejection (severity) 
B: Additional indices analyzed inlate (1988-1992) experience 
Donor-recipient match HLA-A. B. DR 
Recipient PRA 
CPB. cardioputmonary bypass: ARDS. adult respiratory distress yndrome: 
DAD, diffuse alveolar damage; PTLD. posttransplantation lymphoprolif- 
erative disease. 
Results 
Risk factors for OB. In our overall experience, 
airway ischemia, CMV disease, one episode or more 
of  moderate to severe acute rejection (grade II I / IV), 
and three episodes or more of  grade II (or greater) 
acute rejection were identified as significant risk 
factors for the development of  OB by univariate 
analysis (Table VI). However, by multivariate anal- 
ysis, only one risk factor - - three pisodes or more of 
grade II (o r  greater) acute reject ion--was associ- 
ated with the development of  OB. In our early but 
not late experience, CMV disease, late bacterial 
pneumonia, and Pneumocystis nfection were asso- 
ciated with development of OB by univariate anal- 
ysis only. For the late experience group, when HLA 
matching and PRA data were available, fewer 
HLA-DR (--<1) and HLA-B+DR (--2) mismatches 
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Fig. 1. The impact of airway ischemia on freedom from 
the development Of OB between 1982 and 1992. OB was 
more likely to develop in recipients with airway ischemia 
than in those without airway ischemia (t9 < 0.01 by 
generalized Wilcoxon test). 
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Fig. 2. The impact of grade III (or greater) acute rejec- 
tion on freedom from the development of OB between 
1982 and 1992. OB was more likely to develop in recipi- 
ents with one episode or more of grade III (or greater) 
acute rejection than in those with less severe (-< grade II) 
acute rejection (p < 0.01 by generalized Wilcoxon test). 
Table VI. Significant risk factors for the development of OB after lung transplantation 
p Value 
Early period (1982-1987) Late period (1988-1992) Entire period (1982-1992) 
Risk factors for OB Univariate Multivariate Univariate Multivariate Univariate Multivariate 
Airway ischemia 0.007 NS 0.003 NS 0.004 NS 
Late bacterial pneumonia 0.02 NS NS NS NS NS 
CMV disease 0.002 NS NS NS 0.0006 NS 
Pneumocystis 0.02 NS NS NS NS NS 
Acute rejection >- 3 times 0.00001 0.009 0.00001 0.00001 0.00001 0.00001 
Acute rejection grade III/IV 0.0002 0.033 0.00004 0.01 0.0001 NS 
HLA-DR < 1 mismatch ND ND 0.08 NS ND ND 
HLA-B + DR < 2 mismatches ND ND 0.05 NS ND ND 
PRA --> 10% ND ND 0.007 NS ND ND 
NS, Not significant: ND. no data. 
and a PRA activity,of 10% or more were identified 
as risk factors for OB in the univariate analysis 
alone. None of the other indices listed on Table V 
correlated with the subsequent development of OB. 
Time-related risks for development of OB. The 
risk of OB developing was greatest in the first 2 
years after transplantation (Fig. 5). By 2 years after 
transplantation the likelihood of a recipient having 
OB was 47%. Thereafter, the risk of OB developing 
diminished but did not cease and the likelihood of 
the patient having OB at 5 years after transplanta- 
tion increased to 63%. By 5 years after transplanta- 
tion, 75% of recipients with early posttransplanta- 
tion airway ischemia had OB whereas only 60% of 
recipients without airway ischemia had OB (p < 
0.01) (Fig. 1). By 5 years after transplantation, 90% 
of recipients with one episode or more of grade III 
(or greater) acute rejection had OB, whereas only 
40% of recipients with grade II (or less) acute 
rejection had OB (p < 0.01) (Fig. 2). Similarly, 95% 
of recipients who had three or more episodes of 
grade II (or greater) acute rejection had OB, 
whereas only 18% of recipients with two or fewer 
episodes had OB during 5 years of follow-up (Fig. 
3). 
Impact of surveillance TBBx on outcome of OB. 
The overall prevalence of OB was 34% (55/162 at 
risk recipients) (Table II). Concomitant grade II (or 
greater) acute rejection was present in 11 recipients 
(20%) when OB was first detected. All episodes of 
acute rejection resolved with the pulse of aug- 
mented immunosuppression used to treat the OB. 
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acute rejection on development of OB between 1982 and 
1992. OB was more likely to develop in recipients with 
more frequent episodes of acute rejection than in those 
with fewer episodes of acute rejection (p < 0.01 by 
generalized Wilcoxon test). 
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Fig. 4. The severity of OB as assessed by the staging 
categories in Table II at the time of diagnosis and at the 
time of this analysis (April 30, 1993). Dx, Diagnosis; The 
mean stage for group 1 recipients was significantly lower 
than that for recipients in groups 2 to 4 (*p < 0.05 by 
Kruskal-Wallis statistic.) 
In our early experience, only 50% (9/18) of our 
recipients with OB were identified by TBBx (groups 100 
2 and 3) and none were identified by surveillance 
TBBx (group 1) (Table III). In our recent experi- m 80 
ence, 97% (36/37) of recipients with OB were o E 
identified by TBBx and 15 were identified only by g 60 
surveillance TBBx (group 1). 
In the 15 group 1 recipients, which included two 
u_ 40 
recipients with concomitant acute rejection, the OB "~ 
resolved or stabilized in 87% (13/15) of the affected 
recipients after treatment with augmented immuno- 0. 2o 
suppression. Stabilization or resolution of the OB, 
however, occurred in only 38% (5/13) of group 2 (3 0 
with concomitant acute rejection), 24% (4/17) of 
group 3 (4 with concomitant acute rejection), and 
40% (4/10) of group 4 (2 with concomitant acute 
rejection) recipients. Although 30% to 40% of the 
affected recipients in groups 2 to 4 have died'of OB, 
none of the affected recipients in groUp 1 have died 
of this process (p <-0.05 by ~ analysis) (Table IV). 
By definition, recipients in group 1 were in stage 
0 (Table II) at the time of diagnosis, whereas most 
recipients in groups 2 to 4 had experienced a decline 
in pulmonary function by the time OB was identified 
(Fig. 4). Thus the stage or severity of OB in group 1 
recipients was significantly lower than in recipients 
in groups 2 to 4 at the time of diagnosis. More 
important, although the stage of all affected recipi- 
ents increased espite treatment, the stage for group 
1 recipients remained significantly lower than that 
of recipients in groups 2 to 4 at the time of this 
analysis. 
n=162 
r i / i i 
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Fig. 5. Freedom from the development of OB between 
1982 and 1992. 
Discuss ion  
With a prevalence of 34% (55/162 at  risk recipi- 
ents) and a mortality rate of 25% (14/55 affected 
recipients), OB is the most significant long-term 
complication after pulmonary transplantation among 
our patients. Factors predictive of the development 
of OB by univariate analysis for the entire period 
(!982 to 1992) included more frequent and more 
severe acute rejection, CMV disease, and an airway 
ischemic injury early after transplantation (Table 
VI). By multivariate analysis, only three or more 
episodes_ of grade II (or greater) acute r jection 
correlated with the subsequent development of OB. 
Since HLA and PRA data became available in 1988, 
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fewer HLA-DR or HLA-B+DR mismatches and 
greater PRA activity were also associated with the 
development of OB by univariate but not by 
multivariate analysis. From our early experience 
when these infections were more prevalent, late 
bacterial pneumonia, CMV disease, and Pneumo- 
cyst& infection also correlated with the subse- 
quent development of OB by univariate analysis 
only. The factors that did not correlate with the 
development of OB were age at the time of 
operation, gender of donors and recipients and 
their mismatches, type of pretransplantation lu g 
disease, type of transplant procedure, time of 
transplantation, eed for cardiopulmonary by- 
pass, ABO blood group, CMV serologic status 
and their mismatches, and postoperative compli- 
cations of adult respiratory distress syndrome/ 
diffuse alveolar damage, early bacterial pneumo- 
nia, CMV infection, and lymphoproliferative 
disease induced by Epstein-Barr virus. 
These observations reinforce concepts regarding 
the pathogenesis of OB. The strong association 
between frequency and severity of acute rejection 
and the development of OB supports the concept 
that OB occurs as the result of immunologic njury 
directed against he epithelial cells of the airways. 
The association between airway ischemia and the 
subsequent development of OB supports the con- 
cept that OB can also result from an ischemic injury 
that may directly or indirectly alter expression of 
HLA antigens on airway epithelial cells, which then 
leads to immunologic attack. 
An understanding of pathogenesis is the first step 
toward influencing natural history of a disease. The 
longer term goal of this analysis i  to try to eliminate 
or modify risk factors for posttransplantation OB.
Because acute rejection appears to be the most 
important predictor of OB in this study and another 
study, 14 perhaps more potent and sustained immu- 
nosuppression should be given in the early postop- 
erative period to reduce the frequency and severity 
of acute rejection episodes. However. this might 
lead to more problems with infections. Because 
the improvement in early survival has come 
largely from a reduction in the prevalence of early 
infections, which is partly due to the administra- 
tion of less immunosuppression, increasing immu- 
nosuppression could result in more infections and 
hence lower early survival. Nevertheless, this op- 
tion might be warranted in combination with more 
aggressive monitoring and prophylaxis for infec- 
tion. What we really need, however, are better 
immunosuppression agents agents that selec- 
tively suppress allogenic influences while allowing 
intact humoral and cellular immunity to deal with 
invading microorganisms. Efforts to achieve organ 
tolerance via induction of a chimeric state be- 
tween donor and recipient are encouraging steps 
in that direction. 27 
Airway ischemia has not previously been de- 
scribed as a risk factor for OB. 14 Because of the 
occlusive vascular lesions een in the late rejection 
of heart, 28 liver, 29 kidney, 3~ and lung 31'32 al- 
lografts; it is not surprising that an ischemic 
airway injury might be associated with the devel- 
opment of OB. This ischemic injury in lung recip- 
ients most likely occurs from interruption of 
bronchial artery circulation at the time of trans- 
plantation. Perhaps it might be prevented by reanas- 
tomosis of these vessels to the recipient's intratho- 
racic arter~ 3 or ascending or descending thoracic 
aorta. 34 
Contrary to a previous study, t4 this and our 
previous tudies 35' 36 indicate that there is an asso- 
ciation between CMV disease and the subsequent 
development of OB. The common thread between 
these two events may be the immunomodulating 
effect of CMV in altering expression of HLA anti- 
gens on epithelial or endothelial cells rather than a 
direct effect of the virus itself. 37' 38 Gene products of 
CMV infection appear to block the ability of cyclo- 
sporine to inhibit interleukin-2 transcription. 39 Res- 
toration of interleukin-2 production despite the 
presence of cyclosporine could result in normal 
T-cell function with resultant allograft rejection. 
Before the advent of strategies to prevent or treat 
CMV illness, the prevalence of CMV illness was 
76% and the mortality was 27%. 40 Use of CMV- 
negative blood products for seronegative donors 
and recipients and of ganciclovir to prevent and 
treat CMV infection and disease in seropositive 
donors and recipients have decreased the preva- 
lence of CMV illness to 54% and the mortality to 
1%. In our more recent experience, since 1988, the 
relationship between CMV and OB has disappeared 
(Table VI). This change may be due to the beneficial 
effects of the aforementioned measures to prevent 
or modify CMV infection. Other infectious compli- 
cations uch as late bacterial pneumonia nd Pneu- 
mocystis infection, which were significant risk factors 
for OB before 1988, were no longer associated with 
the development of OB in our more recent experi- 
ence. This is also probably because the prevalence of
these infections has decreased ramatically as a 
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result of the prophylactic use of antibiotics. 7'8 
These findings suggest hat eliminating or modi- 
fying risk factors does indeed reduce the preva- 
lence of OB: 
Interestingly, fewer HLA-DR and HLA-B+DR 
mismatches were also associated with OB (Table 
VI). A similar association has also been observed in 
liver transplant recipients, in whom the relationship 
may be due to the permissive ffect of HLA match- 
ing on CMV infection. 41' 42 Among lung recipients, 
HLA-DR matching between the donor and recipi- 
ent does increase the prevalence of CMV disease 
(p = 0.04 by X z analysis, unpublished ata). Thus 
perhaps HLA-DR-restricted immunologic mecha- 
nisms toward antigens including CMV somehow set 
the stage for a subsequent immunologic injury 
against the epithelial cells of the airway or bi le 
duct. 43 If CMV is the "middle man" between 
HLA matching and OB, efforts to eliminate CMV 
infection should favorably affect the prevalence of 
OB. 
Although recipients with a PRA activity of 10% or 
more would be expected to have more problems 
with early humoral rejection, they also appear to be 
at risk for OB. This has also been our experience 
with heart transplant recipients, in whom a PRA 
activity of 10% or more was associated with a 
greater isk of acute and chronic rejection. 21 
This study Supports the concept hat early diag- 
nos is  of OB by surveillance TBBx improves the 
response to treatment. Among recipients whose OB 
was detected by surveillance TBBx in the absence of 
symptoms or change in pulmonary function (group 
1, Stage 0) (Tables III and II, respectively), 88% 
(13/15) are currently in remission with no symptoms, 
pulmonary function changes, or active OB by TBBx. 
When pulmonary function declined (group 2) or 
symptoms were present (group 3) before the diag- 
nosis by TBBx, the likelihood of remission was much 
lower at 39% (5/i3) and 24% (4/17)~ respectively 
(Table IV). Additionally, although none of the 
group 1 recipients have died of OB, four recipients 
(31%) in group 2, and seven recipients (41%) in 
group 3 have died of OB (Table IV). Because 
approximately equal numbers of recipients in each 
of the four groups had concomitant acute rejec- 
tion at the time of the diagnosis of OB, the 
presence of concomitant acute rejection is not likely 
to be the reason for the better outcome of group 1 
recipients. 
Because all recipients with preclinical disease 
were treated with augmented immunosuppression, 
it is not possible to ascertain whether treatment 
affected long-term outcome. Perhaps clinical disease 
would never have developed in some or most of 
these recipients and treatment had no effect on 
long-term outcome. Nevertheless, because un- 
treated OB is most likely a progressive pr0cess, 11' 44 
our findings suggest that diagnosis and treatment of 
OB in the preclinical stage does improve long-term 
outcome. 
Use of TBBx to detect OB remains controversial 
primarily because it appears to be underdiagnosed 
by this technique. Although we have successfully 
used TBBx to identify 82% (45/55) of our recipients 
with OB, 45' 46 others have been less successful. 47
There are several reasons why the diagnosis by 
TBBx may be difficult. First, it may be difficult to 
obtain adequate pieces of lung tissue when OB is 
well established and a lot of subepithelial and 
peribronchial fibrosis is present. Our success with 
TBBx may be the result of our trying to detect he 
process at its earliest stage, presumably before much 
fibrosis and scarring is present. Underdiagnosis may 
also occur because the lesions are patchy and TBBx 
may acquire too few pieces of lung tissue containing 
bronchioles. In this situation, only normal-appear- 
ing airways might be sampled whereas other un 
sampled affected airways might be nearby. On the 
basis of data to accurately detect acute rejection in 
dogs, 48 we consider six adequate-sized pieces of lung 
tissue to be the minimal sample required for a TBBx 
procedure. To reduce sampling error, we obtain 
each piece from a different segment of the lung. To 
ensure that tissue samples contain bronchioles, we 
obtain each piece under fluoroscopic localization 
between 1 to 2 cm from the pleura. Finally, the 
pathologist who examines TBBx specimens from 
three to four recipients per day is more likely to 
recognize OB than the pathologist who examines 
this tissue less frequently. 
In summary, significant risk factors for the devel- 
opment of OB include airway ischemia, CMV dis- 
ease, and especially more severe and frequent epi- 
sodes of acute rejection. Inasmuch as this disorder is 
most likely immunologic n origin, advances in trans- 
plant immunology leading to tolerance between 
donor and recipient, 27 as well as efforts to prevent 
CMV illness 9' 10, 49 and airway ischemic injury, 34 will 
likely be useful preventative measures. Surveillance 
TBBx offers the opportunity to recognize OB in the 
preelinical stage, and this early recognition appears 
to improve response to treatment with augmented 
immunosuppression. 
12 Bando et al. 
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Discussion 
Dr. Bruce A. Reitz (Stanford, Calif.). Dr. Bando and his 
colleagues bring to our attention an important opic, 
because OB is the leading factor limiting the late results of 
lung transplantation, just as coronary artery disease limits 
the late results of heart transplantation. 
This is the largest series of cases of lung transplantation 
(o be presented to date, with a careful analysis of the risk 
factor for OB. Its findings are consistent with smaller 
reported series from the groups at Papworth and Stan- 
ford. 
At Stanford, in 137 patients with various types of lung 
transplants since 1981, OB has been detected with an 
almost identical incidence and has resulted in death in 10 
patients. We also have noted a decline in the incidence of 
OB with the introduction of triple-drug therapy for im- 
munosuppression and with more frequent use of TBBx for 
detection and earlier treatment. 
I have several questions. The immunosuppressive regi- 
men at Pittsburgh in the most recent years has included 
FK 506. Were there any trends suggesting that OB was 
less prevalent in these patients? 
Dr. Bando. Regarding the impact of FK 506 on the 
incidence of OB, we recently started arandomized clinical 
trial comparing cyclosporine and FK 506 for pulmonary 
transplantation. The preliminary results suggested that 
the FK 506 resulted in less acute rejection during the first 
6 months after pulmonary transplantation (Griffith BP, 
Bando K, Hardesty RL, et al. Prospective randomized 
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trial of FK 506 versus cyclosporine after human pulmo- 
nary transplantation. Transplantation 1994;57:848-51). 
Because the frequency and severity of acute rejection are 
the most significant risk factors for the development of 
OB, FK 506 use might result in less OB. However, the 
duration of follow-up is still too short to make any definite 
statement. We will continue to monitor the results of this 
randomized trial and hope to be able to present the 
impact of FK 506 on the development of OB in the future. 
Dr. Reitz. The Pittsburgh team has performed a num- 
ber of studies of the cells recovered at bronchioalveolar 
lavage. Have there been any patterns that might confirm 
the rejection etiology for OB? 
Dr. Bando. Our transplant pathology group has exten- 
sively studied the significance of donor-specific alloreac- 
tivity as assessed by the primed lymphocyte test of cells 
obtained from the allograft by bl'onchoalveolar lavage. 
Although the presence of significant donor-specific allo- 
reactivity does correlate with the presence of acute and 
chronic rejection, the assay is not sufficiently sensitive and 
specific for it to be clinically useful. 
Dr. Reitz. The unexpected findings of a greater inci- 
dence of OB in those patients with fewer mismatches i
contrary to what might be anticipated. Could you com- 
ment further on this? 
Dr. Baudo. I was also puzzled by these results and I 
discussed these results with liver transplant surgeons and 
immunologists. Surprisingly, a similar association has also 
been observed in liver transplant recipients where the 
relationship may be due to the permissive ffect of HLA 
matching on CMV infection. Among lung recipients, 
HLA-DR matching between the donor and recipient 
increases the incidence of CMV disease. Thus perhaps 
HLA-DR-restricted immunologic mechanisms toward 
antigens including CMV somehow set the stage for a 
subsequent immunologic injury against he epithelia ! cells 
of the airway. Thus "CMV" might play a role as a 
"middleman" between HLA matching and OB. 
Dr. Reitz. Looking ahead, are you considering other 
measures that might influence the late development of 
this complication.9 
Dr. Bando. Inasmuch as OB is most likely immunologic 
in origin, advances in transplant immunology leading to 
tolerance between donor and recipient, such as mixed 
chimerism, which is currently being extensively investi- 
gated by Dr. Starzl's group, may have a major impact on 
decreasing the prevalence of this serious late complica- 
tion. Efforts to prevent CMV illness and disease and 
airway ischemic injury will also with be useful preventive 
measures. Our observation that CMV disease is no longer 
a risk factor for the development of OB in parallel with a 
decreasing prevalence of CMV illness and disease suggest 
that elimination or modifying risk factors can decrease the 
likelihood of OB developing. 
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